Inmune Bio, Inc.

Inmune Bio, Inc.

Biotechnology • Healthcare • Boca Raton, FL, United States • INMB (NCM)

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

858 964 3720 225 NE Mizner Blvd., Boca Raton, FL 33432, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

INmune Bio shares slide after Phase II Alzheimer’s trial misses endpoints - Clinical Trials Arena
Clinical Trials Arena • Jul 1
INMune Bio establishes $65 million at-the-market offering - MSN
MSN • Dec 19
INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Yahoo Finance • Sep 8
INmune Bio stock falls after new Alzheimer’s trial data - Investing.com
Investing.com • Dec 1
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Nasdaq • Nov 6

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Inmune Bio, Inc. had layoffs?
No layoff events have been recorded for Inmune Bio, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Inmune Bio, Inc. have?
Inmune Bio, Inc. has approximately 13 employees.
What industry is Inmune Bio, Inc. in?
Inmune Bio, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Inmune Bio, Inc. a publicly traded company?
Yes, Inmune Bio, Inc. is publicly traded under the ticker symbol INMB on the NCM. The company has a market capitalization of approximately $0.05 billion.
Where is Inmune Bio, Inc. headquartered?
Inmune Bio, Inc. is headquartered in Boca Raton, FL, United States at 225 NE Mizner Blvd., Boca Raton, FL 33432, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.